CynapseDx was founded around a sample preparation technology to isolate stem cells from liposuction waste. Later it diverted to address a problem that co-founder Chris Stanley had been unable to resolve a few years previously – namely detection of amyloid-ß in blood samples.
Our sample preperation approach worked well and we soon demonstrated that we could measure levels of both amyloid-ß and α-synuclein in blood in patients with Alzheimer’s, Parkinson’s and Multiple System Atrophy Patients.
One of Damian’s key contributions was designing the experiment using Ficol gradient centrifugation to prove where oligomeric amyloid-ß is located in blood, which is almost entirely on red blood cells.
This finding paved the way to consider blood as a target for treatment, either using drugs like PK051 to disagregate the oligomers on blood cells, or by physically removing blood cells and replacing them with clean cells from healthy donors.